张莉欣,张惠莉

T2DM是一种病理生理机制复杂的慢性代谢性疾病，随着DM病程的进展，需要不同作用机制的降糖药物，纠正多重病理生理缺[1]陷来达到理想的血糖控制。基础胰岛素与胰高血糖素样肽-1受体激动剂(glucagon-like peptide-1 receptor agonist，GLP-1RA)的复合制剂是近年来关注的热点，由基础胰岛素和GLP-1RA组成，具有强效的降糖作用及提高患者依从性，并减少了各组分的不良副作用，如体重增加、低血糖和胃肠道症状。现对基础胰岛素复合制剂和GLP1-RA研究进展作一综述，旨在阐明其作用机理及疗效，为临床提供一定参考。

胰高血糖素样肽-1受体激动剂；胰岛素；复合制剂

[1] ROSENSTOCK J,ARONSON R,GRUNBERGER G,等.Benefits of LixiLan,a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide,Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents:The LixiLan-O Randomized Trial[J/OL].Diabetes Care,2016,39(11):2026-2035. [2] IDF.IDF Diabetes Atlas 2021.https：//diabetesatlas.org/atlas/tenth‐edition/. [3] MONNIER L,LAPINSKI H,COLETTE C.Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients:variations with increasing levels of HbA(1c)[J/OL].Diabetes Care,2003,26(3):881-885. [4] RIDDLE M,UMPIERREZ G,DIGENIO A,等.Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes[J/OL].Diabetes Care,2011,34(12):2508-2514. [5] UEKI K,SASAKO T,OKAZAKI Y,等.Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes(J-DOIT3):an open-label,randomised controlled trial[J/OL].The Lancet.Diabetes&Endocrinology,2017,5(12):951-964. [6] N L,SA H,Y G,等.The Legacy Effect in Type 2 Diabetes:Impact of Early Glycemic Control on Future Complications(The Diabetes&Aging Study)[J/OL].Diabetes care,2019,42(3)[2024-05-09].https://pubmed.ncbi.nlm.nih.gov/30104301/. [7] DAVIES M J,ARODA V R,COLLINS B S,等.Management of Hyperglycemia in Type 2 Diabetes,2022.A Consensus Report by the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)[J/OL].Diabetes Care,2022,45(11):2753-2786. [8] ELSAYEDNA,ALEPPOG,ARODAVR,等.9.PharmacologicApproachestoGlycemicTreatment:StandardsofCareinDiabetes-2023[J/OL]. DiabetesCare,2023,46(Suppl1):S140-S157. [9] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)(上)[J/OL].中国实用内科杂志,2021,41(8):668-695. [10] BALENA R,HENSLEY I E,MILLER S,等.Combination therapy with GLP-1 receptor agonists and basal insulin:a systematic review of the literature[J/OL].Diabetes,Obesity&Metabolism,2013,15(6):485-502. [11] AHMAD E,LIM S,LAMPTEY R,等.Type 2 diabetes[J/OL].The Lancet,2022,400(10365):1803-1820. [12] ANDERSON S L,TRUJILLO J M.Basal Insulin Use With GLP-1 Receptor Agonists[J/OL].Diabetes Spectrum:A Publication of the American Diabetes Association,2016,29(3):152-160. [13] GILBERT M P,PRATLEY R E.GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy:Review of Head-to-Head Clinical Trials[J/OL].Frontiers in Endocrinology,2020,11:178. [14] ENG C,KRAMER C K,ZINMAN B,等.Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes:a systematic review and meta-analysis[J/OL].Lancet(London,England),2014,384(9961):2228-2234. [15] SZÉPKÚTI S,BANDUR S,KOVÁCS G,等.Real-world effectiveness of IDegLira compared with intensified conventional insulin therapy in adults with type 2 diabetes:a retrospective cohort study[J/OL].BMC Endocrine Disorders,2022,22(1):229. [16] GIBBONS C,BLUNDELL J,TETENS HOFF S,等.Effects of oral semaglutide on energy intake,food preference,appetite,control of eating and body weight in subjects with type 2 diabetes[J/OL].Diabetes,Obesity&Metabolism,2021,23(2):581-588. [17] VANA V,LAERKE M K,REHFELD J F,等.Vagal afferent cholecystokinin receptor activation is required for glucagon-like peptide-1-induced satiation[J/OL].Diabetes,Obesity&Metabolism,2022,24(2):268-280. [18] YANG T,CUTSHALL B T,TATARA A,等.Combined Insulin and GLP-1 Receptor Agonists:Simplifying Treatment or Adding Obstacles?[J/OL].Journal of Pharmacy Practice,2019,32(4):447-449. [19] NOVODVORSKÝP,HALUZÍK M.An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus[J/OL].Expert Opinion on Drug Safety,2022,21(3):349-361. [20] MADSBAD S.Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists[J/OL].Diabetes,Obesity&MetaboLis-m,2016,18 (4):317-332. [21] NOMOTO H.Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes[J/OL].World Journal of Diabetes,2023,14(3):188-197. [22] LYSENG-WILLIAMSON K A.Glucagon-Like Peptide-1 Receptor Analogues in Type 2 Diabetes:Their Use and Differential Features[J/OL].Clinical Drug Investigation,2019,39(8):805-819. [23] BROWN E,HEERSPINK H J L,CUTHBERTSON D J,等.SGLT2 inhibitors and GLP-1 receptor agonists:established and emerging indications[J/OL].Lancet(London,England),2021,398(10296):262-276. [24] GOUGH S C L,BODE B W,WOO V C,等.One-year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes:results of a 26-week extension to a 26-week main trial[J/OL].Diabetes,Obesity&Metabolism,2015,17(10):965- 973. [25] PERREAULT L,RODBARD H,VALENTINE V,等.Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes[J/OL].Advances in Therapy,2019,36(2):265-277. [26] KANETO H,KOSHIDA R,BAXTER M.Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes:An innovative solution to a complex therapeutic challenge[J/OL].Diabetes,Obesity&Me- tabolism,2020,22 Suppl 4:24-34. [27] HAEUSLER R A,MCGRAW T E,ACCILI D.Biochemical and cellular properties of insulin receptor signalling[J/OL].Nature Reviews.Molecular Cell Biology,2018,19(1):31-44. [28] ANDERSENA,LUND A,KNOP F K,等.Glucagon-like peptide 1 in health and disease[J/OL].Nature Reviews Endocrinology,2018,14(7):390-403. [29] TUDURÍE,LÓPEZ M,DIÉGUEZ C,等.Glucagon-Like Peptide 1 Analogs and their Effects on Pancreatic Islets[J/OL].Trends in endocrinology and metabolism:TEM,2016,27(5):304-318. [30] MARSO S P,DANIELS G H,BROWN-FRANDSEN K,等.Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes[J/OL].The New England Journal of Medicine,2016,375(4):311-322. [31] GERSTEIN H C,COLHOUN H M,DAGENAIS G R,等.Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND):a double-blind,randomised placebo-controlled trial[J/OL].Lancet(London,England),2019,394(10193):121-130. [32] SP M,SC B,A C,等.Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes[J/OL].The New England journal of medicine,2016,375(19)[2024-05-16].https://pubmed.ncbi.nlm.nih.gov/27633186/. [33] GOUGH S C L,BODE B,WOO V,等.Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide(IDegLira)compared with its components given alone:results of a phase 3,open-label,randomised,26-week,treat-to-target trial in insulin-naive patients with type 2 diabetes[J/OL].The Lancet Diabetes&Endocrinology,2014,2(11):885-893. [34] LINGVAY I,MANGHI F P,GARCÍA-HERNÁNDEZ P,等.Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes:The DUAL V Randomized Clinical Trial[J/OL].JAMA,2016,315(9):898. [35] ARODA V R,ROSENSTOCK J,WYSHAM C,等.Efficacy and Safety of LixiLan,a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin:The LixiLan-L Randomized Trial[J/OL].Diabetes Care,2016,39(11):1972-1980. [36] BUSE J B,VILSBØLL T,THURMAN J,等Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide(IDegLira)[J/OL].Diabetes Care,2014,37(11):2926-2933. [37] LINJAWI S,BODE B W,CHAYKIN L B,等.The Efficacy of IDegLira(Insulin Degludec/Liraglutide Combination)in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy:DUAL III Randomized Clinical Trial[J/OL].Diabetes Therapy:Research,Treatment and Education of Diabetes and Related Disorders,2017,8(1):101-114. [38] RODBARD H W,BODE B W,HARRIS S B,等.Safety and efficacy of insulin degludec/liraglutide(IDegLira)added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes:the DUAL IV trial[J/OL].Diabetic Medicine:A Journal of the British Diabetic Association,2017,34(2):189-196. [39] BILLINGS L K,DOSHI A,GOUET D,等.Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin:The DUAL VII Randomized Clinical Trial[J/OL].Diabetes Care,2018,41(5):1009- 1016. [40] PHILIS-TSIMIKAS A,BILLINGS L K,BUSCH R,等.Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy:A randomized clinical trial in people with uncontrolled type 2 diabetes[J/OL].Diabetes,Obesity&Metabolism,2019,21(6):1399-1408. [41] WATADA H,TAKAMI A,SPRANGER R,等.Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs:The LixiLan JP-O1 Randomized Clinical Trial[J/OL].Diabetes Care,2020,43(6):1249-1257. [42] TERAUCHI Y,NAKAMA T,SPRANGER R,等.Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination(iGlarLixi 1:1)in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs:Arandomized,26-week,open-label, multicentre study:The LixiLan JP-O2 randomized clinical trial[J/OL].Diabetes,Obesity&Metabolism,2020,22 Suppl 4:14-23. [43] KANETO H,TAKAMI A,SPRANGER R,等.Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination(iGlarLixi)in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs:The LixiLan JP-L randomized clinical trial[J/OL].Diabetes,Obesity&Metabolism,2020,22 Suppl 4:3-13. [44] YUAN X,GUO X,ZHANG J,等.Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs:Results from the LixiLan-L-CN randomized controlled trial[J/OL].Diabetes,Obesity&Metabolism,2022,24(11):2182-2191. [45] DI LORETO C,CELLENO R,PEZZUTO D,等.Effectiveness,Simplification and Persistence of IDegLira in Poorly Controlled People with Type 2 Diabetes:A 4-Year Follow-Up Real-World Study[J/OL].Diabetes Therapy:Research,Treatment and Education of Diabetes and Related Disorders,2024,15(6):1313-1331. [46] CAI X,GAO X,YANG W,等.Comparison between insulin degludec/liraglutide treatment and insulin glargine/lixisenatide treatment in type 2 diabetes:a systematic review and meta-analysis[J/OL].Expert Opinion on Pharmacotherapy,2017,18(17):1789-1798. [47] ARONSON R,UMPIERREZ G,STAGER W,等.Insulin glargine/lixisenatide fixed-ratio combination improves glycaemic variability and control without increasing hypoglycaemia[J/OL].Diabetes,Obesity&Metabolism,2019,21(3):726-731. [48] SESTI G,BARDTRUM L,DAGDELEN S,等.A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks:DUAL VIII,a randomized trial designed to resemble clinical practice[J/OL].Diabetes,Obesity&Metabolism,2020,22(5):873-878. [49] BLONDE L,ROSENSTOCK J,DEL PRATO S,等.Switching to iGlarLixi Versus Continuing Daily or Weekly GLP-1 RA in Type 2 Diabetes Inadequately Controlled by GLP-1 RA and Oral Antihyperglycemic Therapy:The LixiLan-G Randomized Clinical Trial[J/OL].Diabetes Care,2019,42(11):2108-2116. [50] WANG W,AGNER B F R,LUO B,等.DUAL I China:Improved glycemic control with IDegLira versus its individual components in a randomized trial with Chinese participants with type 2 diabetes uncontrolled on oral antidiabetic drugs[J/OL].Journal of Diabetes,2022,14(6):401-413. [51] peiy,agnerbr,luob,等.dualiichina:superiorhba1creductionsandweightloss within sulinde gludec/liraglutide(ideglira)versu-sinsulindegludecinarandomizedtrialofchinesepeoplewithtype2diabetesinadequatelycontrolledonbasalinsulin[j/ol].diabetes,obesity&metabolism,2021,23(12):2687-2696. [52] YANG W,DONG X,LI Q,等.Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people withsuboptimally controlled type 2 diabetes on oral agents:The LixiLan-O-AP randomized controlled trial[J/OL].Diabetes,Obesity&Metabolism,2022,24(8):1522-1533. [53] MCCRIMMON R J,FALLA E,SHA J Z,等.Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK[J/OL].Diabetes Therapy:Research,Treatment and Education of Diabetes and Related Disorders,2021,12(12):3217-3230. [54] CANNON A J,BARGIOTA A,BILLINGS L,等.Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets[J/OL].Journal of Managed Care&Specialty Pharmacy,2020,26(2):143-153. [55] PERSANO M,NOLLINO L,SAMBATARO M,等.Real-world study on the effectiveness and safety of basal insulin IDegLira in type 2 diabetic patients previously treated with multi-injective insulin therapy[J/OL].European Review for Medical and Pharmacological Sciences,2021,25(2):923-931.

点击下载PDF